Lycia Therapeutics (LYCA): Valuation Under Pressure

A rival allergy drug cut a key allergic-reaction receptor by 95% and stripped more than 99% of bound IgE from basophils in non-human primates, while Lycia Therapeutics' lead candidate managed only a 50% reduction on the same measure.

Novartis then paid $900 million upfront, with up to $1.1 billion in milestones, to acquire that rival, Excellergy, in March. The comparison sits at the center of a report from Two Natural Capital, which argues Lycia's newly public allergy franchise is hard to value unless Excellergy's program falters. The report does not state the research firm's position in Lycia stock.

Ticker: LYCA (Lycia Therapeutics)
Research Firm: Two Natural Capital
Report URL: https://www.twonaturalcap.com/p/lycia-therapeutics-lyca-bringing?ref=shortreport.fyi
Report date: 2026-11-12
Position Disclosure: Not stated in the source report.

Published by Two Natural Capital on 2026-11-12.

The Short Report's Take

The strongest evidence in this report is a direct, documented contrast: in non-human primates, Lycia's candidate reduced FcεRI expression on basophils by 50%, while Excellergy's candidate reduced it by 95% and removed more than 99% of receptor-bound IgE, according to Two Natural Capital. That gap matters because it was the measure Novartis apparently found compelling enough to pay $900 million upfront, plus up to $1.1 billion in milestones, for Excellergy in March, before Lycia's own IPO. For a holder of LYCA, this is the one comparison in the report that rests on disclosed numbers rather than inference.

Much of the rest is less settled. Two Natural Capital's case that bound IgE removal is the more important mechanism, and that this makes Excellergy's approach superior, is framed as the author's interpretation rather than a head-to-head clinical result. Similarly, Lycia's own claimed advantages (greater IgE clearance, non-weight-based dosing, less frequent dosing) are preclinical and described by the firm as "hoped for" rather than proven. The report cites no regulator or auditor action, and the company had not responded at publication, according to the inputs reviewed.

The source report does not state Lycia's stock price move or short interest, so no market reaction can be reported here.

Related coverage on The Short Report:

Thesis

Two Natural Capital examined Lycia Therapeutics' IPO prospectus and concluded that its IgE-degrading LYTAC platform is difficult to value because a similarly staged rival, Excellergy, now backed by Novartis, appears to have stronger preclinical data.

Distant Clinical Readouts: Lycia's two lead assets (an IgE-mediated food-allergy candidate and a Graves disease candidate) are in Phase 1, with data for both not expected until 2027; a third food-allergy asset is still preclinical.
Imperfect Incumbent: Xolair is FDA-approved across four indications and generated roughly $5.57 billion in worldwide sales in 2025, but only 67% of patients met the primary endpoint in its pivotal OUtMATCH food-allergy trial, leaving 33% without benefit.
Ligelizumab Precedent: Novartis previously developed ligelizumab as a higher-affinity Xolair alternative, but it failed to beat Xolair in Phase 3 chronic urticaria trials and its food-allergy trial was stopped early for lack of superior efficacy.
Unproven Degradation Edge: Lycia's claimed benefits from degrading rather than inhibiting IgE, including treating high-IgE patients and reducing dosing frequency, remain "hoped for" rather than clinically demonstrated, per the report.
Bound-IgE Threat: Excellergy's EXL-111 is described as targeting IgE already bound to allergic effector cells, which the author identifies as the actual driver of allergic reactions, unlike approaches focused mainly on free IgE.
Weaker Primate Data: In non-human primates, Lycia's candidate produced a 50% reduction in basophil FcεRI expression versus Excellergy's 95% reduction and greater than 99% removal of receptor-bound IgE.
No First-Mover Edge: Lycia and Excellergy are described as being at roughly the same development stage, with Lycia's preclinical package lacking a direct comparison to EXL-111 data released in February.
Rising Competitive Bar: GSK paid $2.2 billion for Rapt Therapeutics' Phase 2b candidate ozureprubart, a more potent IgE inhibitor that could become a new treatment standard if it beats Xolair.

Catalysts

Phase 1 data timing: Phase 1 data for Lycia's food-allergy and Graves disease programs, expected in 2027, will be the first human test of whether its IgE-degradation approach outperforms existing therapies.
Rapt/GSK readout: Clinical data from Rapt/GSK's Phase 2b ozureprubart food-allergy program (no date given) could reset the efficacy bar for IgE-targeting drugs.
Novartis/Excellergy updates: Further clinical or preclinical updates from Novartis/Excellergy on EXL-111 (no date given) could widen or narrow the gap with Lycia's candidate.
Pipeline advancement: Advancement of Lycia's third, preclinical food-allergy asset into clinical trials (no date given) would be the next sign of pipeline progress.
Comparative proof points: Any disclosed evidence that Lycia's platform achieves superior efficacy, faster onset, better tolerability, or less frequent dosing versus Xolair, ligelizumab, ozureprubart, or EXL-111 (no date given) would materially affect the thesis.
Competitive setback scenario: A clinical setback for Excellergy's EXL-111 program (no date given) is identified by the author as central to making Lycia's valuation case work.

Company Response

The report does not indicate that Lycia Therapeutics was asked for comment, and no response from the company is mentioned.

Notable Details

Lycia raised more than $300 million in its IPO despite having only one preclinical asset and two Phase 1 assets, with Phase 1 data not expected until 2027.
The report describes Lycia's S-1 as "essentially an apology for the promise of its IgE degraders," even though its Graves disease program is technically the company's most advanced clinical asset.
Xolair's food-allergy launch reportedly outpaced the initial-indication launches of Dupixent and Skyrizi, despite only winning FDA approval for food allergy in February 2024.
Lycia co-founder Carolyn Bertozzi co-authored the foundational 2020 LYTAC paper and later won a Nobel Prize, giving the platform a high-profile scientific pedigree that the report says does not resolve the competitive threat from Excellergy.

"All that said, I think it's tricky to appropriately value Lycia's allergy work unless Excellergy stumbles."

This appears in the report's conclusion, after Two Natural Capital contrasts Lycia's preclinical IgE-degradation data with Excellergy's stronger results and its acquisition by Novartis.

FAQs

What is LYCA stock and when did it go public?

LYCA is the ticker for Lycia Therapeutics, a biotechnology company that went public in an IPO raising more than $300 million, described in the report as happening "late last month." At the time of the IPO, the company had only one preclinical asset and two Phase 1 clinical assets.

What does Lycia Therapeutics do?

Lycia Therapeutics develops LYTACs, or lysosome-targeting chimeras, a platform designed to degrade extracellular and cell-surface proteins by routing them into lysosomes rather than inhibiting them. Its pipeline includes two IgE-mediated food-allergy programs and one Graves disease program, with Phase 1 data for the clinical assets expected in 2027.

What did Two Natural Capital say about Lycia?

Two Natural Capital's report argues that Lycia's food-allergy franchise is hard to value because a similarly staged competitor, Excellergy, showed stronger preclinical results and was subsequently acquired by Novartis. The firm concludes it is "tricky to appropriately value Lycia's allergy work unless Excellergy stumbles."

Why did Novartis pay $900 million for Excellergy?

According to the report, Novartis acquired Excellergy in March for $900 million upfront, with up to $1.1 billion in additional milestone payments, after Excellergy's EXL-111 candidate showed a 95% reduction in FcεRI expression and more than 99% removal of receptor-bound IgE from basophils in non-human primates. Those results compare to a 50% reduction reported for Lycia's candidate on the same measure.

How big is the Xolair market that Lycia is trying to enter?

Xolair generated approximately $5.57 billion in worldwide sales in 2025, with nearly $4 billion of that in the United States, and more than 100,000 U.S. food-allergy patients had been prescribed the drug by 2025. It is approved for four indications, won food-allergy approval in February 2024, and lost exclusivity in late 2025, per the report.

Did Xolair fully solve the food-allergy problem, leaving no room for competitors?

No. In Xolair's pivotal OUtMATCH trial, 67% of the experimental arm met the primary endpoint, meaning 33% did not, and some patients have IgE levels too high to qualify for treatment. The report cites this gap, alongside Xolair's weight-based dosing, as the opening competitors like Lycia, Excellergy, and Rapt/GSK are targeting.

What happened when Novartis previously tried to improve on Xolair with ligelizumab?

Novartis developed ligelizumab as a higher-affinity alternative to Xolair, but it failed to show differentiated efficacy in Phase 3 chronic spontaneous urticaria trials, and its pivotal food-allergy trial was stopped early for lacking superior efficacy versus Xolair. The report uses this history to argue that stronger IgE binding or lowering does not automatically translate into better clinical outcomes.

When will investors get real clinical data on Lycia's approach?

Per the report, Lycia expects Phase 1 data for both of its clinical-stage assets, the IgE-mediated food-allergy program and the Graves disease program, in 2027. The company has said its current cash should fund operations into the second half of 2029 and take all three programs "substantially through" Phase 2 trials.

Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://www.twonaturalcap.com/p/lycia-therapeutics-lyca-bringing, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.